首页 > 市场调查报告书 > 医疗设备

医学影像诊断核子医学

放射性药物市场规模、份额和成长分析（按类型、适应症、系统、应用、最终用户和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1899230

放射性药物市场规模、份额和成长分析（按类型、适应症、系统、应用、最终用户和地区划分）—2026-2033年产业预测

Radiopharmaceuticals Market Size, Share, and Growth Analysis, By Type (Fluorine-18 Derivatives, Technetium-99), By Indication (Diagnosis, Cardiology), By System, By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 210 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，放射性药物市场规模将达到 69.7 亿美元，到 2025 年将达到 72.1 亿美元，到 2033 年将达到 94.2 亿美元，在预测期（2026-2033 年）内复合年增长率为 3.4%。

放射性药物市场分析显示，PET和SPECT等影像技术的进步正在提升医疗保健领域的诊断能力。这些技术利用放射性药物来补充CT和MRI等传统影像方式，提高其特异性和敏感度。高效放射性示踪剂的研发显着提高了诊断准确性，使得癌症、阿兹海默症和心臟病等慢性疾病的早期发现和更详细的特征分析成为可能。这些疾病，尤其是男性前列腺癌的日益普遍，凸显了对先进诊断解决方案日益增长的需求。随着人口老化和慢性病发病率的上升，放射性药物市场预计将显着增长，为参与患者诊断和治疗的利害关係人带来盈利的机会。

全球放射性药物市场按类型、适应症、系统、应用、最终用户和地区进行细分。依成分划分，可分为氟-18衍生物、Technetium-99、镏-177、镓-68、锆-89和其他放射性药物。依适应症划分，可分为诊断、心臟病学和其他适应症。依系统划分，可分为PET和SPECT。依应用划分，可分为肿瘤学、心臟病学、胃肠病学、神经内分泌学、神经病学、肾臟病学和其他应用。依最终用户划分，可分为医院、诊断检查室和其他最终用户。按地区划分，可分为北美、欧洲、亚太地区、中东和非洲以及拉丁美洲。

放射性药物市场成长要素

全球癌症患者数量的不断增长显着推动了对放射性药物的需求。这些特殊化合物在标靶治疗和诊断中发挥着至关重要的作用，能够精准定位肿瘤并最大限度地减少副作用。随着越来越多的人寻求有效的癌症治疗方法，他们越来越依赖放射性药物。这种对个人化癌症治疗日益增长的关注，促使医疗服务提供者和患者都优先考虑能够改善治疗效果和提高患者生活品质的创新解决方案，从而推动了市场的持续扩张。这种情况导致了放射性药物市场的显着成长。

放射性药物市场限制因素

由于严格的法规结构约束放射性药物的生产和核准，该市场面临许多限制因素。製造商在遵守严格的安全和品质标准方面面临许多挑战，这可能导致漫长的核准流程。这些监管壁垒不仅使业内企业的经营环境复杂化，也限制了它们的扩张和创新能力。因此，这种环境可能阻碍市场成长，并阻碍潜在的新进者，最终影响整个放射性药物产业的发展，并限制患者治疗方案的进步。

放射性药物市场趋势

放射性药物市场正经历着向个人化医疗的显着转变，即根据每位患者独特的基因谱和疾病特征量身定制治疗方法。这种转变提高了治疗效果，尤其是在肿瘤学和心臟病学等精准治疗至关重要的领域。因此，越来越多的投资和兴趣投入研发能够提供标靶治疗效果、最大限度提高患者疗效并最大限度降低副作用的放射性药物上。这一发展趋势与更广泛的医疗保健趋势相符，即专注于个人化治疗方案，凸显了个人化解决方案在改善患者预后和推动市场成长方面的重要性。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Cardinal Health（US）
Novartis Company（Switzerland）
Lantheus（US）
Curium（France）
GE HealthCare（US）
Jubilant Pharma Company（India）
China Isotope & Radiation Corporation（China）
Siemens Healthcare GmbH（Germany）
Bracco（Italy）
NTP（South Africa）
Eckert & Ziegler（Germany）
SHINE Technologies, LLC（US）
EczacIbasI-Monrol（Turkey）
IBA Worldwide（Belgium）
Global Medical Solutions（US）
BWX Technologies, Inc.（US）
Institute of Isotopes（Hungary）
Coqui Radiopharmaceuticals Corp.（US）
Evergreen Theragnostics, Inc.（US）
Isotope JSC（Russia）
PharmaLogic Holdings Corp.（US）

简介目录

Product Code: SQMIG35H2263

Radiopharmaceuticals Market size was valued at USD 6.97 Billion in 2024 and is poised to grow from USD 7.21 Billion in 2025 to USD 9.42 Billion by 2033, growing at a CAGR of 3.4% during the forecast period (2026-2033).

Market insights into the radiopharmaceuticals sector reveal that advancements in imaging technologies like PET and SPECT are enhancing diagnostic capabilities within healthcare. These modalities utilize radiopharmaceuticals to provide improved specificity and sensitivity, complementing traditional imaging methods such as CT and MRI. The rising development of effective radiotracers has significantly boosted diagnostic accuracy, leading to earlier detection and better characterization of chronic diseases, including cancer, Alzheimer's disease, and heart disease. The increasing prevalence of these conditions, particularly prostate cancer among men, highlights a growing demand for advanced diagnostic solutions. As the population ages and chronic disease rates continue to climb, the radiopharmaceuticals market is poised for significant growth, presenting lucrative opportunities for stakeholders involved in patient diagnosis and treatment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Radiopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Radiopharmaceuticals Market Segments Analysis

Global Radiopharmaceuticals Market is segmented on the type, indication, system, application, end user, and region. By component, market is segmented into fluorine-18 derivatives, technetium-99, lutetium (Lu) 177, gallium-68, zirconium-89, and others. By indication, market is segmented into diagnosis, cardiology, and others. By system, market is segmented into PET, and SPECT. By Application, the market is segmented into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others. By end user, market is segmented into Hospitals, Diagnostic Labs, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Radiopharmaceuticals Market

The rising prevalence of cancer globally has significantly boosted the demand for radiopharmaceuticals. These specialized compounds play a crucial role in targeted and diagnostic cancer treatments, enabling precise tumor localization while minimizing adverse effects. As more individuals seek effective therapies for cancer management, the reliance on radiopharmaceuticals is becoming increasingly prominent. This heightened focus on tailored cancer care contributes to the ongoing expansion of the market, as healthcare providers and patients alike prioritize innovative solutions that enhance therapeutic outcomes and improve quality of life for those battling the disease. As such, the radiopharmaceuticals market is experiencing substantial growth.

Restraints in the Radiopharmaceuticals Market

The radiopharmaceuticals market faces significant constraints due to a stringent regulatory framework that governs their production and approval. Manufacturers encounter numerous challenges in adhering to rigorous safety and quality standards, which can lead to protracted approval processes. These regulatory hurdles not only complicate the operational landscape for companies within the industry but also restrict their ability to expand and innovate. Consequently, this environment creates barriers to market growth and may deter potential entrants, ultimately impacting the overall development of the radiopharmaceuticals sector and limiting advancements in therapeutic options for patients.

Market Trends of the Radiopharmaceuticals Market

The radiopharmaceuticals market is witnessing a pronounced trend towards personalized medicine, where treatments are specifically designed to cater to the unique genetic profiles and disease characteristics of individual patients. This shift enhances the efficacy of therapies, particularly in oncology and cardiology, where precision is paramount. As a result, there is a growing investment and interest in the development of radiopharmaceuticals that deliver targeted therapeutic outcomes, minimizing side effects and maximizing patient response. This evolution aligns with the broader healthcare focus on customized treatment approaches, underscoring the importance of tailored solutions in improving patient outcomes and driving market growth.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Patent Analysis
Regulatory Landscape
Technological Landscape
PESTEL Analysis
Value Chain Analysis
Supply Chain Analysis

Radiopharmaceuticals Market, By Type

Market Overview
Fluorine-18 Derivatives
- Fluorine-18 Fludeoxyglucose (FDG)
- Fluorine-18 Sodium Fluoride
- Fluorine-18 Flucicovine
- Fluorine-18 Florbetapir
- Fluorine-18 Florbetaben
- Others
Technetium-99
Lutetium (Lu) 177
Gallium-68
- Dotatate
- Dotatoc
Zirconium 89
- 11C-choline
- 14C-urea
Others

Radiopharmaceuticals Market, By Indication

Market Overview
Diagnosis
- Neurology
- Neurodegenerative Disease (AD, PD, and Others)
- Epilepsy
Cardiology
Others

Radiopharmaceuticals Market, By System

Market Overview
PET
- Standalone PET systems
- Hybrid PET/CT
- Hybrid PET/MRI
SPECT

Radiopharmaceuticals Market, By Application

Market Overview
Oncology
Cardiology
Gastroenterology
Neuroendocrinology
Neurology
Nephrology
Others

Radiopharmaceuticals Market, By End User

Market Overview
Hospitals
Diagnostic Labs
Others

Radiopharmaceuticals Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Cardinal Health (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis Company (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curium (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE HealthCare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharma Company (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Isotope & Radiation Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthcare GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NTP (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eckert & Ziegler (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SHINE Technologies, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EczacIbasI-Monrol (Turkey)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IBA Worldwide (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Global Medical Solutions (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BWX Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Institute of Isotopes (Hungary)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coqui Radiopharmaceuticals Corp. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evergreen Theragnostics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Isotope JSC (Russia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PharmaLogic Holdings Corp. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments